Physician profile
Susan M Self
NPI 1023047149
$3,209.84
in general payments reported to CMS, 2019-2025
24 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $712 · 2021: $216 · 2022: $133 · 2023: $217 · 2024: $52.06 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.11 | 2019-2025 | Ubrelvy, Vraylar, Botox |
| Allergan, INC. | $349.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $340.61 | 2019-2020 | |
| Pfizer INC. | $288.60 | 2019-2020 | |
| Novo Nordisk INC | $232.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $168.93 | 2019-2021 | |
| Lilly USA, LLC | $165.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $151.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $75.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.55 | 2019-2020 | |
| Amgen INC. | $63.41 | 2019-2020 | |
| Amarin Pharma, INC. | $62.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.96 | 2019 | |
| Avanir Pharmaceuticals, INC. | $50.43 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $43.84 | 2019 | |
| Daiichi Sankyo INC. | $43.18 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.52 | 2019-2020 | |
| Neos Therapeutics, LP | $30.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.50 | 2020 | |
| Horizon Therapeutics Plc | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.